PainReform AI Stock Analysis
Want to see PRFX full AI Analyst Report?
PainReform (PRFX) AI Stock Analysis
PainReform
(NASDAQ:PRFX)
PRFX scores at the bottom of the range, driven primarily by very weak financial performance: no meaningful revenue, an ~$8.9 million TTM net loss, and operating cash burn that roughly doubled to ~$7.4 million, leaving the company dependent on external financing and exposing shareholders to further dilution. A debt-free balance sheet with ~$15.9 million of equity provides some flexibility but only a limited runway at the current burn rate. Technicals reinforce the caution, with the stock trading well below all key moving averages and negative MACD signaling an entrenched downtrend, though deeply oversold readings leave room for short-term bounces. Valuation provides no cushion given negative earnings and no dividend. With no earnings call commentary or corporate events available, the score rests on fundamentals, trend, and valuation — all of which point to elevated, speculative risk.
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $63.02K
- Dividend Yield
- ―
- Average Volume (3M)
- 229.28K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.64
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
PainReform Business Overview & Revenue Model
Company Description
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a dis...
PainReform Financial Statement Overview
Summary
Financials reflect a pre-commercial development-stage biotech with essentially no revenue (~$40K TTM), a net loss of roughly $8.9 million, and negative gross profit. Operating cash burn nearly doubled year over year to about -$7.4 million, with free cash flow tracking losses almost one-for-one, confirming real cash losses. The lone bright spot is a virtually debt-free balance sheet with ~$15.9 million of equity funding ~83% of assets, but that cushion was built through share issuance rather than profits, implying limited runway at the current burn rate and ongoing dilution risk. Income statement (8) and cash flow (9) scores are extremely weak; the balance sheet (45) only partially offsets them.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
9Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.50K | 17.00K | 0 | 0 | 86.00K | 0 |
| Gross Profit | -121.50K | -827.00K | -16.00K | -15.00K | 71.00K | ― |
| EBITDA | -7.39M | -4.21M | -14.55M | -9.57M | -8.76M | -7.22M |
| Net Income | -8.90M | -4.84M | -14.59M | -9.34M | -8.79M | -7.25M |
Balance Sheet | ||||||
| Total Assets | 19.09M | 12.00M | 4.53M | 9.93M | 12.33M | 19.07M |
| Cash, Cash Equivalents and Short-Term Investments | 11.54M | 4.17M | 4.26M | 8.03M | 4.10M | 16.54M |
| Total Debt | 50.00K | 21.00K | 45.00K | 86.00K | 0 | 0 |
| Total Liabilities | 2.62M | 2.71M | 2.70M | 2.69M | 1.31M | 991.00K |
| Stockholders Equity | 15.87M | 8.54M | 1.82M | 7.24M | 11.02M | 18.08M |
Cash Flow | ||||||
| Free Cash Flow | -7.38M | -3.96M | -12.63M | -6.69M | -6.46M | -6.60M |
| Operating Cash Flow | -7.38M | -3.96M | -12.62M | -6.68M | -6.46M | -6.55M |
| Investing Cash Flow | -3.45M | -982.00K | -13.00K | 5.99M | -6.01M | -50.00K |
| Financing Cash Flow | 14.93M | 3.82M | 8.86M | 4.62M | 0 | 7.48M |
PainReform Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRFX, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.85, and below the 200-day MA of 1.66, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.81 is Neutral, neither overbought nor oversold. The STOCH value of 52.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRFX.
PainReform Risk Analysis
PainReform disclosed 46 risk factors in its most recent earnings report. PainReform reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPainReform Peers Comparison
Overall Rating
CPHI56Neutral
COSM43Neutral
RDHL42Neutral- PRFX37Underperform
SHPH32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CPHI | 56Neutral | $22.29M | -0.51 | -17.14% | ― | -10.97% | 71.83% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| COSM | 43Neutral | $16.30M | -4.91 | -118.89% | ― | 33.82% | 34.05% |
| RDHL | 42Neutral | $3.33M | -0.38 | -438.17% | ― | ― | ― |
| PRFX | 37Underperform | $2.38M | -0.07 | -72.87% | ― | ― | ― |
| SHPH | 32Underperform | $21.58M | -0.15 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRFX | Painreform Ltd. | 0.78 | -3.64 | -82.30% | |
| CPHI | China Pharma | 0.52 | -0.98 | -65.47% | |
| RDHL | RedHill Biopharma Ltd | 0.38 | -0.67 | -63.94% | |
| COSM | Cosmos Holdings | 3.24 | -10.76 | -76.86% | |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | 4.53 | -14.67 | -76.41% |
PainReform Corporate Events
PRF Technologies Faces Court Petition From Activist Shareholder
On November 2, 2026, S.H.N. Financial Investments petitioned the Tel Aviv District Court to compel PRF Technologies Ltd. to convene a special shareholder meeting. S.H.N. seeks to remove three non-external directors and elect its own nominees, while a...
PRF Technologies Signs Term Sheet With Dotz Nano for GridFeed Collaboration
PRF Technologies, a healthcare and sustainable-energy technology company, develops reformulated therapeutics and AI software for renewable-energy forecasting, battery storage optimization and electricity-market trading. On November 3, 2026, it announ...
PRF Technologies Highlights $11 Million Cash, Phase 2 OcuRingâ„¢-K Trial Plans and GridFeed AI Data Center Strategy
On October 23, 2026, PRF Technologies reported preliminary consolidated cash, including short-term deposits, of about $11.0 million and total liabilities of roughly $2.5 million as of September 30, 2026, after raising approximately $10.5 million in g...
PRF Technologies Faces Board Shake-Up Bid from 5.7% Shareholder S.H.N.
On September 24, 2026, PRF Technologies Ltd. received a letter from S.H.N. Financial Investments Ltd., which claims to hold about 5.7% of the company’s voting rights, calling for a special general meeting to remove all directors other than the extern...
PRF Technologies Targets AI Data Centers With GridFeed Power Optimization Push
On September 16, 2026, PRF Technologies announced that GridFeed, its AI-driven energy intelligence and optimization platform, is targeting AI and hyperscale data centers as a strategic growth market amid surging global power demand. Citing Internatio...
PRF Technologies Spins Out GridFeed Unit to Drive AI Renewable Energy Trading Partnerships
PRF Technologies Ltd., a Tel Aviv-based company listed on Nasdaq, straddles healthcare and sustainable energy through reformulated pain-management drugs and AI-powered energy optimization platforms. Its pharma portfolio includes candidates like OcuRi...
PRF Technologies Posts Wider First-Half 2026 Loss but Bolsters Cash and Equity
On September 3, 2026, PRF Technologies reported unaudited financial results for the six months ended June 30, 2026, highlighting a modest $14,000 in revenue and an operating loss of $2.5 million. The company’s net loss before tax widened to $2.9 mill...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026